MY206712A - Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication - Google Patents

Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Info

Publication number
MY206712A
MY206712A MYPI2021007563A MYPI2021007563A MY206712A MY 206712 A MY206712 A MY 206712A MY PI2021007563 A MYPI2021007563 A MY PI2021007563A MY PI2021007563 A MYPI2021007563 A MY PI2021007563A MY 206712 A MY206712 A MY 206712A
Authority
MY
Malaysia
Prior art keywords
immunodeficiency virus
human immunodeficiency
pyrido
inhibitors
virus replication
Prior art date
Application number
MYPI2021007563A
Other languages
English (en)
Inventor
P Gillis Eric
IWUAGWU Christiana
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MY206712A publication Critical patent/MY206712A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2021007563A 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication MY206712A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
MY206712A true MY206712A (en) 2025-01-03

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021007563A MY206712A (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Country Status (34)

Country Link
US (2) US12129255B2 (pl)
EP (1) EP3986561B1 (pl)
JP (1) JP7628512B2 (pl)
KR (1) KR102932817B1 (pl)
CN (2) CN119039288A (pl)
AR (1) AR119174A1 (pl)
AU (1) AU2020295793B2 (pl)
BR (1) BR112021025655A2 (pl)
CA (1) CA3143136A1 (pl)
CL (1) CL2021003388A1 (pl)
CO (1) CO2021017479A2 (pl)
CR (1) CR20210664A (pl)
DK (1) DK3986561T3 (pl)
ES (1) ES2974541T3 (pl)
FI (1) FI3986561T3 (pl)
HR (1) HRP20240501T1 (pl)
HU (1) HUE065762T2 (pl)
IL (1) IL288750B2 (pl)
LT (1) LT3986561T (pl)
MA (1) MA56526B1 (pl)
MD (1) MD3986561T2 (pl)
MX (1) MX2021016149A (pl)
MY (1) MY206712A (pl)
PE (1) PE20220510A1 (pl)
PH (1) PH12021553180A1 (pl)
PL (1) PL3986561T3 (pl)
PT (1) PT3986561T (pl)
RS (1) RS65304B1 (pl)
SI (1) SI3986561T1 (pl)
SM (1) SMT202400153T1 (pl)
TW (1) TWI850403B (pl)
UA (1) UA128967C2 (pl)
UY (1) UY38755A (pl)
WO (1) WO2020254985A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084492A1 (en) 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MX2021016149A (es) 2019-06-19 2022-05-18 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
CA3138332A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
EP4037661A1 (en) * 2019-10-01 2022-08-10 VIIV Healthcare Company Method for treating hiv with cabotegravir and rilpivirine
MX2022006940A (es) * 2019-12-09 2022-07-11 Viiv Healthcare Co Composiciones farmaceuticas.
IL296182A (en) * 2020-03-06 2022-11-01 Viiv Healthcare Uk No 5 Ltd Inhibitors of human immunodeficiency virus replication
MX2022012881A (es) * 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
US20240423985A1 (en) * 2021-10-13 2024-12-26 Viiv Healthcare Uk (No.5) Limit-Ed Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52489B (sr) 2001-02-02 2013-02-28 Bristol-Myers Squibb Company Kompozicija i antivirusna aktivnost derivata supstituisanog azaindoloksoacetat piperazina
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CN102143962B (zh) * 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP6205354B2 (ja) 2011-07-06 2017-09-27 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
WO2014110298A1 (en) 2013-01-09 2014-07-17 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
PT2943493T (pt) 2013-01-09 2017-10-23 Gilead Sciences Inc Compostos terapêuticos para o tratamento de infecções virais
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
JP6491321B2 (ja) 2014-08-29 2019-03-27 ギリアード サイエンシーズ， インコーポレイテッド 抗レトロウイルス剤
DK3347352T3 (da) * 2016-08-19 2019-08-26 Gilead Sciences Inc Terapeutiske forbindelser anvendelige til profylaktisk eller terapeutisk behandling af en hiv-virusinfektion
US10640499B2 (en) * 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2020084492A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2021016149A (es) 2019-06-19 2022-05-18 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
DK3986561T3 (da) 2024-03-04
KR102932817B1 (ko) 2026-03-04
PH12021553180A1 (en) 2022-11-07
FI3986561T3 (fi) 2024-05-02
UY38755A (es) 2020-11-30
CL2021003388A1 (es) 2022-09-30
EP3986561B1 (en) 2024-02-14
MA56526A (fr) 2022-04-27
US12129255B2 (en) 2024-10-29
KR20220024608A (ko) 2022-03-03
UA128967C2 (uk) 2024-12-11
HRP20240501T1 (hr) 2024-07-05
BR112021025655A2 (pt) 2022-02-01
SI3986561T1 (sl) 2024-04-30
TW202115055A (zh) 2021-04-16
US20210323967A1 (en) 2021-10-21
MD3986561T2 (ro) 2024-06-30
AR119174A1 (es) 2021-12-01
JP2022537047A (ja) 2022-08-23
PL3986561T3 (pl) 2024-06-10
EP3986561A1 (en) 2022-04-27
IL288750A (en) 2022-02-01
ES2974541T3 (es) 2024-06-27
LT3986561T (lt) 2024-04-25
HUE065762T2 (hu) 2024-06-28
US20250019383A1 (en) 2025-01-16
IL288750B2 (en) 2025-04-01
MA56526B1 (fr) 2024-05-31
AU2020295793B2 (en) 2023-07-06
CO2021017479A2 (es) 2022-04-19
CN114245795B (zh) 2024-08-06
MX2021016149A (es) 2022-05-18
TWI850403B (zh) 2024-08-01
CN114245795A (zh) 2022-03-25
JP7628512B2 (ja) 2025-02-10
PT3986561T (pt) 2024-03-15
CA3143136A1 (en) 2020-12-24
CN119039288A (zh) 2024-11-29
SMT202400153T1 (it) 2024-05-14
RS65304B1 (sr) 2024-04-30
WO2020254985A1 (en) 2020-12-24
AU2020295793A1 (en) 2022-01-20
CR20210664A (es) 2022-01-21
IL288750B1 (en) 2024-12-01
PE20220510A1 (es) 2022-04-07

Similar Documents

Publication Publication Date Title
MY206712A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
PH12021550813A1 (en) Inhibitors of human immunodeficiency virus replication
MY174224A (en) Hepatitis b virus surface antigen inhibitor
MX2024015459A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2025011432A (es) Profarmacos antivirales y formulaciones de los mismos
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AR082079A1 (es) Derivados del acido 2-naftalen-acetico, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de la proliferacion del virus hiv
TN2016000090A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors.
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12021552191A1 (en) Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases
WO2010042391A3 (en) Hiv integrase inhibitors
MX2022011016A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
WO2006121831A3 (en) Hiv integrase inhibitors
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
AU2006299042A8 (en) HIV integrase inhibitors
ZA202310682B (en) Nicotinamide ripk1 inhibitors
GEP20207100B (en) New derivatives of adamantix benzimidazole as anthelmin- tic, antiviral and antibacterial agents